General Information
|
|
Product
|
Visfatin Antibody FITC-Conjugated
|
Description
|
FITC-Conjugated Nicotinamide phosphoribosyltransferase precursor Antibody N-epitope
|
Verified Applications
|
ELISA, IHC, IP, WB
|
Host
|
Rabbit
|
Species Cross Reactivity
|
Human, Rat
|
Immunogen
|
N-epitope synthetic peptide taken within amino acid region 200-300 on human Visfatin protein.
|
Accession #
|
NCBI: NP_005737.1
|
Physical Properties
|
|
Quantity
|
100 µg
|
Volume
|
200 µl
|
Concentration
|
0.68-0.70 µg/µl in antibody stabilization buffer
|
Form
|
FITC-Conjugated
|
Clonality
|
Polyclonal
|
Determinant
|
N-epitope
|
Storage
|
-20⁰C for long term storage
|
Application Protocol
|
DB
|
1:4,000
|
ELISA
|
1:4,000
|
Immunohistochemistry |
1:50-1:100 |
Immunoprecipitation
|
1:150
|
Western Blot
|
1:500
|
Protein
|
Uniprot #
|
P43490
|
Overview
|
Catalyzes the condensation of nicotinamide with 5-phosphoribosyl-1-pyrophosphate to yield nicotinamide mononucleotide, an intermediate in the biosynthesis of NAD. It is the rate limiting component in the mammalian NAD biosynthesis pathway. The secreted form behaves both as a cytokine with immunomodulating properties and an adipokine with anti-diabetic properties, it has no enzymatic activity, partly because of lack of activation by ATP, which has a low level in extracellular space and plasma.
|
Molecular Function
|
Cytokine, Glycosyltransferase, Transferase
|
Subcellular Location
|
Nucleus, Cytoplasm, Secreted
|
Expression
|
Expressed in large amounts in bone marrow, liver tissue, and muscle. Also present in heart, placenta, lung, and kidney tissues.
|
Structure
|
Homodimer
|
Alternative Nomenclature
|
1110035O14Rik antibody
AI314458 antibody
AI480535 antibody
DKFZP666B131 antibody
EC 2.4.2.12 antibody
MGC117256 antibody
NAmPRTase antibody
Nampt antibody
Nicotinamide phosphoribosyltransferase antibody
PBEF antibody
PBEF1 antibody
Pre B cell colony enhancing factor antibody
Pre B cell enhancing factor antibody
VF antibody
Visfatin antibody
|
|
|